Loading
companiesCompany
Cambridge Cancer Genomics (CCG.ai)
CCG.ai built software to combine genomic and clinical data so oncologists could choose and adjust treatment sooner. The company is no longer active.
Overview
Cambridge Cancer Genomics developed a data-driven precision oncology platform: software to analyse tumour and liquid biopsy sequencing alongside clinical records, and machine-learned biomarkers intended to predict treatment response and detect relapse earlier than imaging. It grew to a team of about 25 in Cambridge before the YC directory marked it inactive. It is recorded as wound down; no acquirer is named because none was found in a primary source.
Headquarters
Cambridge, GB
Funding
All startupsWound downYC S17
Investors
Type
Stage
Wound down · Y Combinator Summer 2017
Website
Similar pages
- CompanyBillionToOne
Shares Y Combinator, Comprehensive genomic profiling, Liquid biopsy (ctDNA) and the tag yc.
- CompanyDelee
Shares Y Combinator, Liquid biopsy (ctDNA) and the tag yc.
- CompanyAOA Dx
Shares Y Combinator, Liquid biopsy (ctDNA) and the tag yc.
- CompanyYemaachi Biotech
Shares Y Combinator, Comprehensive genomic profiling and the tag yc.
- CompanyOncobox
Shares Y Combinator, Comprehensive genomic profiling and the tag yc.
- CompanyNumen
Shares Y Combinator, Liquid biopsy (ctDNA) and the tag yc.
- CompanyOmanta
Shares Y Combinator, Comprehensive genomic profiling and the tag yc.
- CompanyData Driven Bioscience (Duoseq)
Shares Y Combinator, Comprehensive genomic profiling and the tag yc.